This concept is supported by that genetic mutations or stimuli of PPARγ regulates development of PAH both in vivo and in vitro (Hansmann et al., 2008; Gong et al., 2011; Calvier et al., 2017, 2019). Here, PPARG is linked to pulmonary arterial hypertension.